| Literature DB >> 26410746 |
Pierangelo Barbero1, Marco Busso2, Marco Tinivella3, Carlo Alberto Artusi4, Stefania De Mercanti4, Angele Cucci4, Andrea Veltri2, Paolo Avagnina3, Andrea Calvo5, Adriano Chio'5, Luca Durelli4, Marinella Clerico4.
Abstract
Literature provides reports only of a limited follow-up single injection of botulinum toxin-A (BoNT-A) in patients with sialorrhea. The aim of our study is to evaluate the long-lasting efficacy and safety of ultrasound-guided BoNT-A injections for severe sialorrhea secondary to neurological dysphagia. We enrolled 38 severe adult sialorrhea patients referred consecutively to the neurology unit and performed bilateral parotid and submandibular gland BoNT-A injections under ultrasound guidance. The outcomes of the study were reduction of sialorrhea, duration of therapeutic effect, and subjective patient- and caregiver-reported satisfaction. A total of 113 BoNT-A administrations were given during the study period with a mean duration of follow-up of 20.2 ± 4.4 months. We observed a significant decrease from baseline in mean number of daily aspirations and a significant improvement in patient- and caregiver-reported outcomes following ultrasound-guided BoNT-A injections (p < 0.001 vs baseline for all comparisons) and the mean duration of the efficacy was 5.6 ± 1 months. No major treatment-related adverse events occurred and a low incidence of minor adverse events was reported. This study confirms the long-lasting efficacy and safety of ultrasound-guided BoNT-A injections for sialorrhea, regardless of the causative neurological disorder. These results should encourage the use of BoNT-A in the treatment of severe sialorrhea and highlight the role of ultrasound guidance to obtain optimal results in terms of safety and reproducible outcomes.Entities:
Keywords: Botulinum toxin; Drooling; Dysphagia; Neurological diseases; Sialorrhea; Ultrasound-guided botulinum toxin-A injections
Mesh:
Substances:
Year: 2015 PMID: 26410746 DOI: 10.1007/s00415-015-7894-1
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849